167 related articles for article (PubMed ID: 21805176)
1. Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series.
Covelli M; Lanciano E; Tartaglia P; Grattagliano V; Angelelli G; Atzeni F; Sarzi-Puttini P; Lapadula G
Rheumatol Int; 2012 Oct; 32(10):3281-4. PubMed ID: 21805176
[TBL] [Abstract][Full Text] [Related]
2. FcRL4
Haacke EA; Bootsma H; Spijkervet FKL; Visser A; Vissink A; Kluin PM; Kroese FGM
J Autoimmun; 2017 Jul; 81():90-98. PubMed ID: 28390747
[TBL] [Abstract][Full Text] [Related]
3. [Successful treatment with rituximab in a patient with primary thymic MALT lymphoma complicated with acquired von Willebrand syndrome and Sjögren syndrome].
Iwabuchi T; Kimura Y; Suzuki T; Hayashi H; Fujimoto H; Hashimoto Y; Ogawa T; Kusama H; Fukutake K; Ohyashiki K
Rinsho Ketsueki; 2011 Apr; 52(4):210-5. PubMed ID: 21566407
[TBL] [Abstract][Full Text] [Related]
4. [Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: preliminary data].
Logvinenko OA; Vasil'ev VI; Sedyshev SKh; Safonova TN; Rodionova EB; Kokosadze NV; Aleksandrova EN; Cherkasova MV; Radenska-Lopovok SG; Nasonov EL
Ter Arkh; 2012; 84(12):88-96. PubMed ID: 23479998
[TBL] [Abstract][Full Text] [Related]
5. A patient with primary Sjogren's syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review.
Wise LM; Arkfeld DG
Clin Rheumatol; 2020 Apr; 39(4):1357-1362. PubMed ID: 31863212
[TBL] [Abstract][Full Text] [Related]
6. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
7. [MALT-type parotid lymphoma--a case report and the review of the literature].
Wierzbicka M; Bartochowska A; Kopeć T; Szyfter W
Otolaryngol Pol; 2013; 67(1):61-5. PubMed ID: 23374667
[TBL] [Abstract][Full Text] [Related]
8. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren's syndrome: a retrospective clinical study.
Pollard RP; Pijpe J; Bootsma H; Spijkervet FK; Kluin PM; Roodenburg JL; Kallenberg CG; Vissink A; van Imhoff GW
J Rheumatol; 2011 Oct; 38(10):2198-208. PubMed ID: 21844152
[TBL] [Abstract][Full Text] [Related]
9. Primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue-type in the thymus of a patient with Sjögren's syndrome and rheumatoid arthritis.
Kim JM
J Korean Med Sci; 2003 Dec; 18(6):897-900. PubMed ID: 14676452
[TBL] [Abstract][Full Text] [Related]
10. Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren's syndrome are not predictive for parotid MALT lymphoma development.
Haacke EA; van der Vegt B; Vissink A; Spijkervet FKL; Bootsma H; Kroese FGM
Ann Rheum Dis; 2017 Oct; 76(10):1781-1784. PubMed ID: 28710097
[TBL] [Abstract][Full Text] [Related]
11. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma.
Pijpe J; van Imhoff GW; Vissink A; van der Wal JE; Kluin PM; Spijkervet FK; Kallenberg CG; Bootsma H
Ann Rheum Dis; 2005 Jun; 64(6):958-60. PubMed ID: 15576414
[TBL] [Abstract][Full Text] [Related]
12. [The relationship between Sjogren's syndrome, systemic sclerosis and lymphoproliferative diseases].
Vasil'ev VI; Chal'tsev BD; Gorodetskii VR; Pal'shina SG; Shornikova NS; Anan'eva LP; Gaiduk IV; Kokosadze NV; Probatova NA; Pavlovskaia AI; Rodionova EB; Safonova TN; Balabina AA
Ter Arkh; 2020 Dec; 92(12):126-136. PubMed ID: 33720584
[TBL] [Abstract][Full Text] [Related]
13. Parotid gland non-Hodgkin lymphoma in primary Sjögren syndrome.
Zenone T
Rheumatol Int; 2012 May; 32(5):1387-90. PubMed ID: 21431292
[TBL] [Abstract][Full Text] [Related]
14. [Association between thymic MALT lymphoma and Sjögren's syndrome].
Giroux Leprieur E; Antoine M; Gounant V; Copie-Bergman C; Lavole A; Milleron B
Rev Pneumol Clin; 2009 Apr; 65(2):108-12. PubMed ID: 19375051
[TBL] [Abstract][Full Text] [Related]
15. [Development of MALT-lymphoma in Sjögren syndrome].
Vissink A; van der Meij EH; Spijkervet FKL
Ned Tijdschr Tandheelkd; 2020 Oct; 127(10):543-550. PubMed ID: 33156295
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjogren's syndrome-associated B-cell non-Hodgkin's lymphoma.
Carbone J; Perez-Fernandez R; Muñoz A; Sabin P; Carreño L; Fernandez-Cruz E
Clin Rev Allergy Immunol; 2008 Feb; 34(1):80-4. PubMed ID: 18270861
[TBL] [Abstract][Full Text] [Related]
17. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy.
Shih WJ; Ghesani N; Hongming Z; Alavi A; Schusper S; Mozley D
Clin Nucl Med; 2002 Feb; 27(2):142-3. PubMed ID: 11786752
[No Abstract] [Full Text] [Related]
18. Diagnostic role of CXCL13 biomarker in primary Sjogren's syndrome patients with parotid non-Hodgkin's lymphoma complication.
Badarinza M; Serban O; Maghear L; Pelea MA; Rosca RI; Fodor D; Stancu B
Med Clin (Barc); 2023 Jun; 160(11):484-488. PubMed ID: 37005121
[TBL] [Abstract][Full Text] [Related]
19. Investigation of three potential autoantibodies in Sjogren's syndrome and associated MALT lymphoma.
Cui L; Elzakra N; Xu S; Xiao GG; Yang Y; Hu S
Oncotarget; 2017 May; 8(18):30039-30049. PubMed ID: 28404907
[TBL] [Abstract][Full Text] [Related]
20. Clinical, histopathological and immunohistological study of lymphoid disorders in the parotid gland of patients with Sjögren's syndrome.
Bozinović MT; Katić V; Krasić D; Veselinović D; Jovanović P; Krstić M
Vojnosanit Pregl; 2009 Dec; 66(12):955-60. PubMed ID: 20095514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
